ETH
HUMAW icon

Exos TFP Holdings’s Humacyte Inc Warrant HUMAW Stock Holding History

Exos TFP Holdings’s Portfolio HUMAW Stock Details HUMAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-17,500
Closed -$12.6K – 192
2023
Q3 		$12.6K Hold
17,500
– – 0.01% 154
2023
Q2 		$12.8K Sell
17,500
-9,651
-36% -$7.8K 0.01% 165
2023
Q1 		$16.3K Hold
27,151
– – ﹤0.01% 356
2022
Q4 		$10.7K Hold
27,151
– – ﹤0.01% 412
2022
Q3 		$30K Buy
+27,151
New +$30K 0.01% 334

Other funds holding HUMAW

JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Exos TFP Holdings's HUMAW Position: Q4 2023 in Review

Exos TFP Holdings sold out of Humacyte Inc Warrant (HUMAW) in Q4 2023, closing a stake of 17,500 shares — an estimated $12.6K sold.

Exos TFP Holdings first reported a position in HUMAW in Q3 2022 and held it in 5 quarters. The position peaked at $30K in Q3 2022. 9 funds tracked by Wall St. Rank hold HUMAW as of Q4 2023.

  • Exos TFP Holdings reported no remaining Humacyte Inc Warrant position as of Q4 2023 after selling out during the quarter.
  • Exos TFP Holdings sold 17,500 Humacyte Inc Warrant shares in Q4 2023, an estimated $12.6K.
  • Exos TFP Holdings first reported a position in Humacyte Inc Warrant in Q3 2022 and held it in 5 quarters.
  • Exos TFP Holdings's Humacyte Inc Warrant position peaked at $30K in Q3 2022.
  • 9 funds tracked by Wall St. Rank held Humacyte Inc Warrant as of Q4 2023.

Based on Exos TFP Holdings's 13F filing for Q4 2023, filed 14 Feb 2024.